JOP20220027A1 - تركيبات من تروفينتايد - Google Patents
تركيبات من تروفينتايدInfo
- Publication number
- JOP20220027A1 JOP20220027A1 JOP/2022/0027A JOP20220027A JOP20220027A1 JO P20220027 A1 JOP20220027 A1 JO P20220027A1 JO P20220027 A JOP20220027 A JO P20220027A JO P20220027 A1 JOP20220027 A1 JO P20220027A1
- Authority
- JO
- Jordan
- Prior art keywords
- compositions
- compounds
- products
- methods
- disclosure describes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/18—Carbon
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882998P | 2019-08-05 | 2019-08-05 | |
| PCT/US2020/044733 WO2021026066A1 (en) | 2019-08-05 | 2020-08-03 | Compositions of trofinetide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20220027A1 true JOP20220027A1 (ar) | 2023-01-30 |
Family
ID=74502416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2022/0027A JOP20220027A1 (ar) | 2019-08-05 | 2022-02-01 | تركيبات من تروفينتايد |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11370755B2 (OSRAM) |
| EP (1) | EP4009962A4 (OSRAM) |
| JP (2) | JP2022543391A (OSRAM) |
| KR (1) | KR20220059479A (OSRAM) |
| CN (1) | CN114667136A (OSRAM) |
| AU (1) | AU2020324396B2 (OSRAM) |
| BR (1) | BR112022002229A2 (OSRAM) |
| CA (1) | CA3149633A1 (OSRAM) |
| CL (1) | CL2022000301A1 (OSRAM) |
| CO (1) | CO2022002616A2 (OSRAM) |
| IL (1) | IL290324A (OSRAM) |
| JO (1) | JOP20220027A1 (OSRAM) |
| MX (1) | MX2022001505A (OSRAM) |
| MY (1) | MY206115A (OSRAM) |
| SA (1) | SA522431585B1 (OSRAM) |
| WO (1) | WO2021026066A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114667136A (zh) | 2019-08-05 | 2022-06-24 | 诺仁制药有限公司 | Trofinetide的组合物 |
| US11827600B2 (en) * | 2021-07-12 | 2023-11-28 | Acadia Pharmaceuticals Inc. | Crystalline forms of trofinetide |
| WO2025169163A1 (en) * | 2024-02-10 | 2025-08-14 | Teadus Pharma Private Limited | Method for the synthesis of trofinetide and its analogues |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2573765B1 (fr) * | 1984-11-23 | 1988-06-10 | Solvay | Procede pour la synthese de peptides |
| WO2006127702A2 (en) * | 2005-05-23 | 2006-11-30 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| US7863304B2 (en) | 2001-05-24 | 2011-01-04 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| ATE435852T1 (de) | 2001-05-24 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Gpe-analoga und peptidomimetika |
| US8637567B2 (en) | 2001-05-24 | 2014-01-28 | Neuren Pharmaceuticals Ltd. | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid |
| US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
| WO2007106555A2 (en) | 2006-03-14 | 2007-09-20 | Neuren Pharmaceuticals Limited | Oral formulations of glycyl-2-methylprolyl-glutamate |
| EP2060580A1 (en) * | 2007-11-19 | 2009-05-20 | SOLVAY (Société Anonyme) | Process for the manufacture of persilylated peptides |
| SI2667715T1 (sl) * | 2011-01-27 | 2017-11-30 | Neuren Pharmaceuticals Limited | Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline |
| US20150224164A1 (en) * | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| CN114667136A (zh) * | 2019-08-05 | 2022-06-24 | 诺仁制药有限公司 | Trofinetide的组合物 |
-
2020
- 2020-08-03 CN CN202080062340.0A patent/CN114667136A/zh active Pending
- 2020-08-03 AU AU2020324396A patent/AU2020324396B2/en active Active
- 2020-08-03 JP JP2022506639A patent/JP2022543391A/ja not_active Withdrawn
- 2020-08-03 MX MX2022001505A patent/MX2022001505A/es unknown
- 2020-08-03 MY MYPI2022000626A patent/MY206115A/en unknown
- 2020-08-03 CA CA3149633A patent/CA3149633A1/en active Pending
- 2020-08-03 EP EP20850753.3A patent/EP4009962A4/en active Pending
- 2020-08-03 BR BR112022002229A patent/BR112022002229A2/pt unknown
- 2020-08-03 KR KR1020227006982A patent/KR20220059479A/ko active Pending
- 2020-08-03 WO PCT/US2020/044733 patent/WO2021026066A1/en not_active Ceased
-
2021
- 2021-06-14 US US17/347,135 patent/US11370755B2/en active Active
-
2022
- 2022-02-01 JO JOP/2022/0027A patent/JOP20220027A1/ar unknown
- 2022-02-03 SA SA522431585A patent/SA522431585B1/ar unknown
- 2022-02-03 IL IL290324A patent/IL290324A/en unknown
- 2022-02-04 CL CL2022000301A patent/CL2022000301A1/es unknown
- 2022-03-04 CO CONC2022/0002616A patent/CO2022002616A2/es unknown
- 2022-06-23 US US17/847,736 patent/US11866406B2/en active Active
-
2023
- 2023-11-21 US US18/516,604 patent/US12297172B2/en active Active
-
2026
- 2026-01-13 JP JP2026003598A patent/JP2026063085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022543391A (ja) | 2022-10-12 |
| SA522431585B1 (ar) | 2025-02-13 |
| MY206115A (en) | 2024-11-29 |
| CN114667136A (zh) | 2022-06-24 |
| IL290324A (en) | 2022-04-01 |
| CL2022000301A1 (es) | 2022-09-20 |
| US11866406B2 (en) | 2024-01-09 |
| US20220055987A1 (en) | 2022-02-24 |
| CO2022002616A2 (es) | 2022-06-10 |
| CA3149633A1 (en) | 2021-02-11 |
| MX2022001505A (es) | 2022-03-11 |
| EP4009962A1 (en) | 2022-06-15 |
| US12297172B2 (en) | 2025-05-13 |
| KR20220059479A (ko) | 2022-05-10 |
| AU2020324396B2 (en) | 2025-07-03 |
| US20220324799A1 (en) | 2022-10-13 |
| BR112022002229A2 (pt) | 2022-04-19 |
| US11370755B2 (en) | 2022-06-28 |
| JP2026063085A (ja) | 2026-04-10 |
| US20240109841A1 (en) | 2024-04-04 |
| WO2021026066A1 (en) | 2021-02-11 |
| EP4009962A4 (en) | 2023-08-09 |
| AU2020324396A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551062A1 (en) | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways | |
| WO2020160193A3 (en) | Compounds and uses thereof | |
| MX388750B (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| MX380907B (es) | Compuestos útiles como inhibidores de cinasa. | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| EA201100311A1 (ru) | Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы | |
| EA201400624A1 (ru) | Замещенные 4-фенилпиридины для лечения болезней, связанных с рецептором nk-1 | |
| PH12019502605A1 (en) | Glucuronide prodrugs of janus kinase inhibitors | |
| SA519410320B1 (ar) | مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل | |
| EP4356969A3 (en) | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | |
| MX2017014035A (es) | Formas solidas novedosas. | |
| EA202090414A1 (ru) | Соединения и их применение | |
| SA522431585B1 (ar) | تركيبات تروفينتايد | |
| EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
| PH12021551058A1 (en) | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | |
| EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| MX2021008510A (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina. | |
| MX2015013419A (es) | Cianoetilpirazolo piridonas aciclicas como inhibidores de janus quinasa. | |
| MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
| PH12016501393A1 (en) | Substituted bicyclic heteroaryl compounds as rxr agonists | |
| ZA202001295B (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
| JOP20210332A1 (ar) | عقاقير أولية لمعدلات المستقبل nmda | |
| MX385475B (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa | |
| MX2019000276A (es) | Nuevos derivados ciclopropílicos. |